Pulmonary Medicine

Host: Jacob Sands, MD

Guest: Biagio Ricciuti, MD

Treatment for lung cancer can be complex, but PL-L1 expression and tumor mutational burden might help us select the best treatment for our patients. What do we need to know about the role of these biomarkers in the treatment of lung cancer? To discuss this, Dr. Jacob Sands is joined by Dr. Biagio Ricciuti, a medical oncologist at the Dana-Farber Cancer Institute.

Guest: Jason Goldman, MD

How are standard versus adjuvanted influenza vaccines made? Here to break down the manufacturing process for these types of influenza vaccines is primary care physician Dr. Jason Goldman.

Host: Marius M. Hoeper, MD

A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of this trial and explores how they may impact patients with PAH.

Host: Stephanie Christenson, MD

Guest: Ron Balkissoon, MD, MSc, DIH, FRCPC

What do we need to know about the pathophysiology and burden of COPD exacerbations? To better understand this—and the factors that may put our patients at risk—Dr. Stephanie Christenson from the University of California San Francisco and Dr. Ron Balkissoon from National Jewish Health share insights on COPD exacerbations.

This is a non-promotional, non-CME disease state educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Host: Stephanie Christenson, MD

Guest: Ron Balkissoon, MD, MSc, DIH, FRCPC

What is a COPD exacerbation, and what puts our patients at risk of them? Drs. Stephanie Christenson and Ron Balkissoon discuss these risks and the burden of COPD exacerbations on our patients.

This is a non-promotional, non-CME disease state educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Host: Randy Young, MD

Guest: Daniel Jay Feinstein, MD, FACP, MS, ACRP-PI

Diagnosing pneumonia can be challenging, but the CAP guidelines offer recommendations to improve the detection of this infection. To find out more about the recommendations, Dr. Randy Young and Dr. Daniel Feinstein, a Physician Executive at Novant Health, dive into testing for pneumonia.

This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by bioMèrieux.

Host: Randy Young, MD

Guest: Tufik Assad, MD, MSCI

What are the factors that make diagnosing pneumonia challenging, and how might emerging testing modalities improve that? To answer this question, Dr. Randy Young and Dr. Tufik Assad from the Williamson Medical Center in Franklin, Tennessee dive into the etiology, diagnostic challenges, and current trends in pneumonia diagnostics.

This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by bioMèrieux.

Host: Frank C. Sciurba, MD, FCCP

Guest: Emily L. Yee, MD

What do we need to know about using endobronchial valves in patients with severe COPD and emphysema? Drs. Frank Sciurba and Emily Yee explore the impact of these valves on patients.

This educational podcast is produced in partnership with the American College of CHEST Physicians and sponsored by Pulmonx Corporation, the manufacturer of Zephyr. Click here to find additional educational resources for clinicians and patients.

Host: Matthew Sorrentino, MD

Guest: Michael A. Solomon, MD, MBA

Guest: Sean Agbor-Enoh, MD, PhD

Pulmonary arterial hypertension (PAH) is a rare, and even fatal, condition that can impair the chest and lungs. But could a new blood test help us better assess disease severity and survivability in patients with PAH? To dive deeper into this topic, Dr. Matthew Sorrentino is joined by Dr. Michael Solomon and Dr. Sean Agbor-Enoh from the National Institutes of Health.

Host: Jacob Sands, MD

Guest: Edward B. Garon, MD, MS

Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.